All studies involving MRL/MpJ


Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Ackert1 body size and weight Body weight, body length, body mass index. Aging study, 6mo, 12mo, 20mo. None BMI, BW inbred   (32) both 26, 52, 87 wks 2008
Ackert1 DXA Body mass, fat mass, lean mass, bone mineral density and content, body area, bone area. Aging study, 6mo, 12mo, 20mo. bone area, body area BMD inbred   (32) both 26, 52, 87 wks 2008
Benavides1 genotype assessment Gpr84 allele assessment. PCR, sequencing. None None inbred w/CC8   (58) both 6wks 2013
Berndt1 ventilator
with methacholine
Airway resistance. Baseline vs. methacholine-challenged (several doses). None MCh inbred   (37) both 9-12wks 2010
Berndt4 histopathology Lung adenoma frequency and severity at 20mo. Tumor incidence, cancer, aging. None None inbred   (28) both 87wks 2011
Boon1 body weight
with influenza A (H5N1) virus
Influenza A (H5N1) virus (several doses) vs. baseline. None BW, flu inbred   (23) f 6-9wks 2011
Boon1 health assessment
with influenza A (H5N1) virus
Survival rate, influenza A (H5N1) virus (several doses). Strain H5N1 susceptibility score. None flu inbred   (23) f 6-9wks 2011
Bopp1 health assessment
with Plasmodium berghei
Susceptibility, Plasmodium berghei (malaria). Parasitemia in blood and distribution in brain, spleen, lungs, liver. None None inbred   (31) both 8-12wks 2010
Broad2 genotyping SNP profiling, 131,000+ genomic locations, 1-19,X. None SNPs inbred   (89) 2009
CGD-MDA1 genotyping SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. None SNPs inbred   (142) m 2014
CGDpheno1 body size and weight Body weight and length. None BW inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 complete blood count Hematology. Cell counts, white cells, lymphocytes, neutrophils, monocytes, eosinophils, red cell parameters, hemoglobin, hematocrit, reticulocytes, platelets CBC, RBC, WBC, CHCM, EOS, HCT, HGB, LYM, MCH, MCHC, MONO, MPV, NEUT, PLT, RET, RETIC inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 DXA Body mass, fat mass, lean mass, bone mineral density. None BMD inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. None CHOL, FFA, TG inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 metabolic panel Clinical blood chemistry (plasma). 4h fast. glucose, bilirubin, urea nitrogen, thyroxine, chloride, potassium, sodium, dissolved carbon dioxide BIL, CO2, GLU, T4, TBIL, chem inbred w/CC8   (72) both 10-13wks 2009
Chen1 immune cell quantification Natural killer T cells in peripheral blood, spleen, thymus. invariant. iNK, expressing CD4 None inbred   (38) both 8-10wks 2011
Crowley1 behavior observation
with haloperidol
Observed involuntary repetitive movement. Baseline vs. during and after haloperidol 60d implant (several timepoints). tongue protrusion, overt or subtle chewing movement, jaw tremor None inbred w/CC8   (27) m 9-28wks 2012
Crowley1 body weight
with haloperidol
Baseline vs. after haloperidol 60d implant. None BW inbred w/CC8   (27) m 9-28wks 2012
Crowley1 drug and metabolite quantification
with haloperidol
Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). None None inbred w/CC8   (27) m 9-28wks 2012
Crowley1 inclined screen test
with haloperidol
Baseline vs. during and after haloperidol 60d implant (several timepoints). extrapyramidal side effects, EPS None inbred w/CC8   (27) m 9-28wks 2012
Crowley1 open field test
with haloperidol
Locomotor activity, exploratory behavior, involuntary movement. Baseline vs. haloperidol 60d implant (several timepoints). 60 min test. None OFT inbred w/CC8   (27) m 9-28wks 2012
Dietrich1 in vitro assay
with Bacillus anthracis lethal toxin
Bacillus anthracis lethal toxin (anthrax) susceptibility. None None inbred   (50) f 6-8wks* 1998
Gros1 genotype assessment
with Candida albicans
C5 allele sufficiency or deficiency. None None inbred   (36) f 8-12wks 2011
Gros1 in vitro assay
with Candida albicans
Susceptibility to infection with Candida albicans. colony-forming units in kidney, fungal load None inbred   (36) f 8-12wks 2011
Gros2 health assessment
with Plasmodium chabaudi
Survival score and susceptibility, Plasmodium chabaudi. None None inbred   (25) both 8-10wks 2012
Gros2 microscopy
with Plasmodium chabaudi
Percent of Plasmodium chabaudi-infected erythrocytes in blood. None None inbred   (25) both 8-10wks 2012
Harrill1 body weight
with isoniazid
Body weight. Isoniazid-treated vs. control. None None inbred   (34) f 8-10wks 2011
Harrill1 histopathology
with isoniazid
Liver pathology scores. Isoniazid-treated vs. control. lymphohistiocytic, hepatocytic None inbred   (34) f 8-10wks 2011
Harrill1 lipid profile
with isoniazid
Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. None CHOL, TG inbred   (34) f 8-10wks 2011
Harrill1 metabolic panel
with isoniazid
Alanine transaminase. Isoniazid-treated vs. control. alanine transaminase ALT inbred   (34) f 8-10wks 2011
Harrill1 organ weights
with isoniazid
Body, liver, kidney weights. Isoniazid-treated vs. control. None None inbred   (34) f 8-10wks 2011
Harrill2 biomarker quantification
with DB289
Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. None KIM-1, KIM1 inbred   (34) f 6-8wks 2012
Harrill2 body weight
with DB289
DB289-treated vs. control. None BW inbred   (34) f 6-8wks 2012
Harrill2 drug and metabolite quantification
with DB289
Kidney metabolite (DB75) concentration. DB289-treated vs. control. None None inbred   (34) f 6-8wks 2012
Harrill2 metabolic panel
with DB289
Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. None ALT, BUN, CREA inbred   (34) f 6-8wks 2012
Harrill2 organ weights
with DB289
Kidney and liver weights. DB289-treated vs. control. None LW inbred   (34) f 6-8wks 2012
Harrill2 urinalysis
with DB289
Urine volume, creatinine. DB289-treated vs. control. kidney CREA inbred   (34) f 6-8wks 2012
Jax5 colony observation Reproductive performance. age first litter, litters born, mice per litter, mice per dam, percent weaned, time intervals, parenting index, fecundity index None inbred   (35) f various 2009
Johnson1 ABR test Auditory brainstem response. None ABR inbred   (51) both 3-12wks and 15-72wks 2000
Jones1 vestibular stimulus test Vestibular function using evoked potentials. threshold stimulus response level, latency and amplitude of evoked potentials None inbred   (16) both 49-63wks 2003
Korstanje1 urinalysis Microalbumin, creatinine, ratio. Aging study, 6mo, 12mo, and 20mo. kidney Alb, CREA, MA inbred   (30) both 52, 78, 104 wks 2008
Korstanje2 histopathology Kidney pathology. Aging study, 6mo, 12mo, 20mo. percent of glomeruli exhibiting mesangial matrix expansion None inbred   (29) m 52, 78, 104 wks 2013
Lightfoot1 body weight Body weight None BW inbred   (41) both 8-9wks 2010
Lightfoot1 running wheel monitoring Distance, duration, speed. None None inbred   (41) both 8-9wks 2010
Massett1 body weight Body weight None BW inbred   (34) both 8wks 2012
Massett1 treadmill endurance test Duration, distance, work. None None inbred   (34) both 8wks 2012
Mills1 apoptosis assessment Aging study, 6mo, 12mo, 20mo. apoptotic splenocytes None inbred   (30) both 26, 52, 87 wks 2008
Mills1 chromosome instability assessment Chromosome instability. Aging study, 6mo, 12mo, 20mo. reticulocytes with micronuclei, cell damage RET, RETIC inbred   (30) both 26, 52, 87 wks 2008
Mogil3 nociception assay von Frey nociception test, baseline and after spared nerve injury (SNI) surgery as a hypersensitizer. None None inbred   (18) both 7-12wks 2012
Morgan1 body weight
with high-fat diet and olanzapine
Body weight and growth curve from age 8wks to 18wks weighed every 2wks. Olanzapine vs. control (both groups high-fat diet). None BW inbred w/CC8   (9) f 8-18wks 2014
Peters4 complete blood count Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. cell counts, white cells, lymphocytes, neutrophils, monocytes, basophils, eosinophils, large unstained cells, red cell parameters, hemoglobin, hematocrit, reticulocytes, platelets BASO, CBC, RBC, WBC, CHCM, EOS, HCT, HGB, LUC, LYM, MCH, MCHC, MONO, MPV, NEUT, PLT, RET, RETIC inbred   (30) both 26, 52, 78, 104 wks 2007
Petkova1 complete blood count Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. white cell count, lymphocytes, neutrophils, eosinophils, monocytes CBC, RBC, WBC, EOS, LYM, MONO, NEUT inbred   (32) both 26, 52, 78, 104 wks 2007
Petkova1 immune cell quantification Aging study, 6mo, 12mo, 18mo, 24mo. B cells. Natural killer cells, total, mature, T cells total, CD4, CD8, naive, central memory, effector cells None inbred   (32) both 26, 52, 78, 104 wks 2007
Pletcher1 body weight Body weight None BW inbred   (32) m 7-9wks 2007
Pletcher1 hormone quantification Corticosterone (serum). None None inbred   (32) m 7-9wks 2007
Pletcher1 open field test Locomotor and anxiety-related behavior. 7 min test. None OFT inbred   (32) m 7-9wks 2007
Pletcher1 tail suspension test Immobility percentage. immobility percentage, hopelessness, depression TST inbred   (32) m 7-9wks 2007
Rice1 proteomic profiling Hair proteomics analysis. Spectral counts for 46 specific proteins. integumentary None inbred   (11) both 10-19wks 2012
Richfield1 neurotransmitter quantification Neurotransmitters. Molecular measures. 3-4-dihydroxyphenylacetic acid, DOPAC, 4-hydroxy-3-methoxyphenylacetic acid, HVA, serotonin, 5HT, dopamine turnover HVA, SHT inbred   (15) m 7-9wks 2003
Richfield1 open field test Locomotor activity. 3 day trials. 45 min sessions. None OFT inbred   (15) m 7-9wks 2003
Sandell1 health assessment Post-injury wound healing. Ear cartilage and articular cartilage. None None LGXSM w/par   (15) both 6-7wks 2012
Sandell1 histopathology Post-injury wound healing. Articular cartilage at 12wks and 16wks post-injury. None None LGXSM w/par   (15) both 6-7wks 2012
Seburn2 gait analysis Aging study, 6mo, 18mo. stride length, track width, stride frequency, stance time, swing time, stride time, ratios None inbred   (32) both 26, 52, 78, 104 wks 2008
Seburn2 grip strength Peak tension. 3 trials. Aging study, 6mo, 12mo, 18mo, 24mo. None None inbred   (32) both 26, 52, 78, 104 wks 2008
Sugiyama1 tail cuff Heart rate and blood pressure. Conscious mice. None BP, HR inbred   (25) m 10wks 2007
Sundberg1 study archive Histopathology. Aging study. None None inbred   (28) both 2008
Tarantino1 body weight
with cocaine
Body weight None BW inbred   (45) m 8-11wks 2015
Tarantino1 open field test
with cocaine
Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. None OFT inbred   (45) m 8-11wks 2015
Tarantino2 forced swim test
with ovariectomy
Mice with ovariectomy surgery vs. controls (sham surgery), 6 min test. immobility time, hopelessness, depression None inbred   (37) f 8-10wks 2016
Tarantino2 open field test
with ovariectomy
Locomotor activity and exploratory behavior. Mice with ovariectomy surgery vs. controls (sham surgery), 10 min test. None OFT inbred   (37) f 8-10wks 2016
UCLA1 genotyping SNP profiling, 132,000+ genomic locations, 1-19,X None SNPs HMDP   (248) both 2018
Vulpe1 mineral quantification Liver mineral levels. Iron, copper, zinc. Iron homeostasis. None None inbred   (18) both 8wks 2010
Vulpe1 transferrin quantification Diferric transferrin (plasma). None None inbred   (18) both 8wks 2010
Wiltshire1 elevated plus maze Locomotor activity. None EPM inbred   (38) both 12-14wks 2010
Wiltshire1 light-dark box Light-dark test. Anxiety-related behavior. None None inbred   (38) both 12-14wks 2010
Wiltshire1 open field test Locomotor activity. None OFT inbred   (38) both 12-14wks 2010
Wiltshire2 drug and metabolite quantification
with fluoxetine
Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. None None inbred   (30) m 9-11wks 2011
Wiltshire2 open field test
with fluoxetine
Locomotor activity, exploratory and anxiety-related behavior. Fluoxetine-treated vs. control. 7 min test. None OFT inbred   (30) m 9-11wks 2011
Wiltshire2 tail suspension test
with fluoxetine
Immobility. Fluoxetine-treated vs. control. 5 min test. immobility time, hopelessness, depression TST inbred   (30) m 9-11wks 2011
Wiltshire3 biomarker quantification
with fluoxetine
Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. cerebral cortex None inbred   (30) m 10-11wks 2011
Xing1 ECG Heart rate and wave intervals. Conscious. Aging study, 6mo, 12mo, 20mo. None ECG, EKG, HR inbred   (29) both 26, 52, 87 wks 2008
Xing2 gait analysis Aging study, 6mo, 12mo, 18mo. None None inbred   (31) both 26, 52, 78 wks 2010
Yuan1 body weight Aging study, 6mo, 12mo, and 18mo. None BW inbred   (33) both 26, 52, 78 wks 2007
Yuan1 hormone quantification Insulin-like growth factor 1 (serum). Aging study, 6mo, 12mo, and 18mo. None IGF-1, IGF1, INS inbred   (33) both 26, 52, 78 wks 2007
Yuan2 colony observation Life span study. Survival curves. Aging study. None None inbred   (31) both max lifespan 2007
Yuan3 lipid profile Cholesterol (HDL). Aging study, 6mo, 12mo, 18mo. 4h fast, plasma. None CHOL inbred   (32) both 26, 52, 78 wks 2008
Yuan3 metabolic panel Clinical blood chemistry. Aging study, 6mo, 12mo, 18mo. albumin, thyroxine, total protein, bilirubin, urea nitrogen, disolved carbon dioxide. Iron, calcium, chloride, magnesium, phosphorus, potassium, sodium. Alkaline phosphatase, alanine transaminase, lipase ALP, ALT, Alb, BIL, CO2, LIP, T4, TBIL, TP, chem inbred   (32) both 26, 52, 78 wks 2008
Yuan4 colony observation Observed age at vaginal opening (patency). Aging study. None None inbred   (33) f 2-9wks 2009
Zheng1 tympanometry Middle ear function. compliance, volume, gradient, pressure None inbred   (61) both 15-51d 2008